Shipping calculated by weight — US, Canada, Mexico & Europe
Ponyon
CJC-1295 No DAC / Modified GRF (1-29)

CJC-1295 No DAC / Modified GRF (1-29)

品牌: Ponyon

CJC-1295 No DAC, commonly referred to as Modified GRF (1-29), is a short-acting GHRH analog research peptide studied for GHRH receptor signaling, pituitary growth hormone (GH) release, pulsatile GH secretion, and GH/IGF-1 axis-related endocrine mechanisms.

US$42.00
有货
CJC-1295(None DAC)
1

SKU CJC1295N-2MG_10 · 30 天内可退货

CJC-1295 No DAC is a synthetic research peptide related to GHRH (Growth Hormone-Releasing Hormone). In the research-peptide market, the term “CJC-1295 No DAC” is commonly used to refer to Modified GRF (1-29), a short-acting GHRH analog.

Unlike CJC-1295 with DAC, this version does not incorporate a Drug Affinity Complex (DAC) modification and therefore lacks the albumin-binding design responsible for the prolonged pharmacokinetic profile of the DAC-containing form. This makes it relevant to research involving shorter-duration and pulsatile GHRH/GH signaling.

In endocrine research, CJC-1295 No DAC is investigated in connection with GHRH receptor activation, pituitary GH release, pulsatile growth hormone signaling, the GH/IGF-1 axis, and associated endocrine and metabolic regulatory mechanisms.

It can also serve as an experimental tool for comparing short-acting GHRH analogs with DAC-containing long-acting analogs in terms of receptor signaling, duration of activity, and endocrine responses.

CJC-1295 No DAC / Modified GRF (1-29) remains a research compound and should not be represented as having established muscle-building, fat-loss, anti-aging, or performance-enhancing effects in humans.

用户评价

暂无评价

来写下第一条评价吧。

完善你的方案

* 以上声明未经美国食品药品监督管理局(FDA)评估。本产品不用于诊断、治疗、治愈或预防任何疾病。孕期、哺乳期、服药或患有疾病者请先咨询医生。